Bovie intends to finalize the development and commercialization of the technology. As part of the agreement, Bovie granted a license to Boston Scientific until 2016 to uses outside of those fields listed above.
This agreement replaces a previously signed distribution and marketing agreement between the companies’ for the technology’s use in Boston Scientifics’s oncology business. The original development and manufacturing agreement signed in 2007 required Bovie to develop and manufacture certain products using Boston Scientifics’s intellectual property.
Andrew Makrides, president of Bovie Medical, said: “Adding strength to Bovie’s new product line, Mr Bob Rioux, who was at the forefront of the Boston Scientific tissue resection program, is joining Bovie as vice president of Advanced Resection Technologies. Mr Rioux’s combination of technical and marketing skills makes him ideally suited to commercialize these new products.”